FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
PRINCETON, N.J., March 03, 2016 -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that Al Altomari, President and Chief Executive Officer will present at the 28th Annual ROTH Conference on Monday, March 14, 2016 at 7:30 AM Pacific Time.
To access the live and archived webcast of the presentation, visit the Investor Relations section of Agile Therapeutics website at www.agiletherapeutics.com. The webcast will be archived on Agile Therapeutics website for 60 days following the event.
About Agile
Agile Therapeutics is a women’s health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products. Our product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adherence and patient acceptability. For more information, please visit the company website at www.agiletherapeutics.com.
Contact: Mary Coleman 609-683-1880
